Notice: Images are for illustration only and may not reflect the exact product you receive. Brand-name medications may look different depending on their country of origin—Canadian versions, for example, often include a "PR" symbol on the packaging. Rest assured, the medication, dosage, and active ingredients will be exactly as prescribed. Canada Pharmacy Store is committed to your health and safety, and we work only with licensed pharmacies to ensure you receive trusted, high-quality medication every time.
General Medication Fact Sheet for Selzentry
| Field | Information |
|---|---|
| Medication Name | Selzentry |
| Generic Name | Maraviroc |
| Boxed/Label Warning | Hepatotoxicity (liver damage) has been reported. Patients should be monitored. |
| Purpose | Antiretroviral medication used to treat HIV-1 infection. |
| Mechanism of Action | CCR5 co-receptor antagonist; blocks HIV-1 entry into cells by binding to the CCR5 receptor. |
| Dosage Forms | Oral tablets |
| Available Strengths | 25 mg, 75 mg, 150 mg, 300 mg |
| Dosage Frequency | Twice daily, with or without food, in combination with other antiretroviral medications. |
| Common Side Effects | Cough, fever, upper respiratory tract infections, rash, dizziness, nausea, diarrhea. |
| Serious Side Effects | Hepatotoxicity (liver damage), severe allergic reactions, postural hypotension, increased risk of certain infections. |
| Drug Interactions | Strong CYP3A inhibitors (e.g., ketoconazole, itraconazole, clarithromycin), strong CYP3A inducers (e.g., rifampin, St. John’s Wort), certain other antiretroviral medications. |
| Important Notes | Must be used in combination with other antiretroviral medications; baseline tropism testing is required to determine if the patient’s HIV-1 strain uses the CCR5 receptor; use with caution in patients with liver disease. |
| Storage | Store at room temperature away from moisture and light. |
| Missed Dose | Take as soon as you remember; if it is almost time for your next dose, skip the missed dose and continue with your regular dosing schedule. Do not double the dose. |
| Alternatives | Truvada (emtricitabine/tenofovir disoproxil), Descovy (emtricitabine/tenofovir alafenamide), Isentress (raltegravir). |
Selzentry Alternatives
| Medication | Mechanism of Action | Notes |
|---|---|---|
| Truvada (emtricitabine/tenofovir disoproxil) | Nucleoside reverse transcriptase inhibitors (NRTIs) | A combination drug used as part of HIV treatment or for PrEP. |
| Descovy (emtricitabine/tenofovir alafenamide) | Nucleoside reverse transcriptase inhibitors (NRTIs) | Similar to Truvada, but with a different form of tenofovir. Used in HIV treatment or for PrEP. |
| Isentress (raltegravir) | Integrase strand transfer inhibitor (INSTI) | Inhibits the integration of HIV DNA into host cell DNA. |
Selzentry Side Effects
| Common Side Effects | Serious Side Effects |
|---|---|
| Cough | Hepatotoxicity (liver damage) |
| Fever | Severe allergic reactions (anaphylaxis) |
| Upper respiratory tract infections | Postural hypotension (dizziness upon standing) |
| Rash | Increased risk of certain infections (e.g., pneumonia) |
| Dizziness | Myocardial Ischemia/Infarction |
| Nausea | Severe Skin Reactions |
| Diarrhea | Immune Reconstitution Syndrome |
Selzentry Dosage Guide
| Condition | Starting Dose | Maintenance Dose | Administration Notes |
|---|---|---|---|
| HIV-1 Infection (with CYP3A inhibitors) | 150 mg twice daily | 150 mg twice daily | Adjusted based on concomitant medications and renal function. |
| HIV-1 Infection (with CYP3A inducers) | 600 mg twice daily | 600 mg twice daily | Adjusted based on concomitant medications and renal function. |
| HIV-1 Infection (without CYP3A inhibitors or inducers) | 300 mg twice daily | 300 mg twice daily | Adjusted based on concomitant medications and renal function. |
Selzentry Price With And Without Insurance
| Purchase Context | Estimated Price |
|---|---|
| With Insurance | $100 |
| Without Insurance (U.S.) | $1800 |
| From CPS | $950 |
